Dapagliflozin slows eGFR decline in diabetics

Dapagliflozin is able to delay renal disease progression among patients with type 2 diabetes, even in those with normal kidney function, according to a study presented at the recently concluded Kidney Week 2019 of the American Society of Nephrology (ASN 2019).

Read More: https://specialty.mims.com/topic/dapagliflozin-slows-egfr-decline-in-diabetics?channel=multi-specialty&elq_mid=49584&elq_cid=38342